Curanex Pharmaceuticals Inc Common Stock (CURX) — Cash Flow-to-Debt Ratio
Curanex Pharmaceuticals Inc Common Stock (CURX) has a Cash Flow-to-Debt Ratio of -49.40x as of September 2025, meaning its operating cash flow of $-9.19 Million could theoretically repay -49% of its total liabilities ($185.96K) in one year. See Curanex Pharmaceuticals Inc Common Stock free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Curanex Pharmaceuticals Inc Common Stock Cash Flow-to-Debt Ratio (2023–2024)
Historical debt coverage capacity for Curanex Pharmaceuticals Inc Common Stock across 2 annual periods. Also explore Curanex Pharmaceuticals Inc Common Stock (CURX) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Curanex Pharmaceuticals Inc Common Stock (2023–2024)
Year-by-year debt coverage analysis for Curanex Pharmaceuticals Inc Common Stock. For market capitalisation and broader financial context, see CURX market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -38.12x | $-555.58K | $14.57K | ▼ -453381.3% |
| 2023 | -0.01x | $-120.00 | $14.28K | — |